Table 1.

Colitis reporting and odds ratios of reporting for PI3K inhibitors within the WHO global safety database.

Pi3Kinhibitor	Target	Colitis Cases	Non-Cases	Reporting OR (95% CI)
	-	342	10,801	9.5 (8.6–10.6)
Idelalisib	PI3Kδ	296	6093	14.6 (13.0–16.4)
Alpelisib	PI3Kα	27	4092	2.0 (1.4–2.9)
Duvelisib	PI3Kγ/PI3Kδ	16	365	13.2 (8.0–21.7)
Copanlisib	All PI3K	3	172	5.2 (1.7–16.4)
Umbralisib	PI3Kδ	1	82	-